-
Menarini and Radius Announce Positive Topline Results for Phase 3
Time of Update: 2021-12-04
-The study meets the two primary endpoints of ER+/HER2-advanced or metastatic breast cancer (mBC) patients-Elacestrant is the first oral SERD to show positive top-line results in key clinical trials as a monotherapy in ER+HER2 advanced or mBC treatment compared with SoC-Elacestrant prolongs the PFS of the total patient group and ESR1 mutation subgroup-Plans to submit regulatory documents in the U.
-
TCR2 and Bristol-Myers Squibb form a partnership to evaluate mesothelin-positive solid tumor cell therapy
Time of Update: 2021-12-04
The main purpose of this phase 2 trial is to evaluate the efficacy of gavo-cel in patients with unresectable, metastatic or recurrent mesothelin-expressing solid tumors, including non-small cell lung cancer (NSCLC), ovarian cancer, and malignant pleura/peritoneum Mesothelioma (MPM) and cholangiocarcinoma .
-
Kangfang Biology is rapidly advancing the phase II clinical study of IL-4Rα monoclonal antibody atopic dermatitis and asthma
Time of Update: 2021-12-04
About AK120AK120 is a new type of autoimmune disease treatment drug that targets IL-4Rα independently developed by Kangfang Biology.
-
Beihai Kangcheng obtained the global authorization of the Scriptr Global Stitchr(TM) technology platform and cooperated in the development of neuromuscular disease gene therapy
Time of Update: 2021-12-04
Beihai Kangcheng will have the exclusive global license of Scriptr Global to develop, produce and commercialize gene therapy candidates for dystrophin disease by using the company's Stitchr™ platform (a proprietary ribozyme-mediated RNA assembly technology) Product .
-
There are new clues to "starve" cancer cells through diet
Time of Update: 2021-12-04
Science and Technology Daily, Beijing, October 24 (Reporter Zhang Mengran) According to a cancer study recently published in the British journal Nature, a team of American scientists described the latest clue to "starve" cancer cells by restricting calories-dietary patterns inhibit the pancreas The unique mechanism of tumor growth in a mouse model of cancer .
-
Visualizing three-dimensional gastric organoids reveals a new mechanism for cell renewal quality control
Time of Update: 2021-12-04
Researchers combined the gastric organoid system and single organ metabolic mass spectrometry analysis to analyze the chemical modification of Helicobacter pylori that interferes with the renewal quality of gastric epithelial cells, and found that the cell division spindle plasticity regulation The 66th lysine of machine EB1 is the physiological substrate of TIP60.
-
New crown vaccine blockbuster data released!
Time of Update: 2021-12-04
Characteristics of participants who signed up for clinical trialsResearchers found that before the booster shot, compared with Pfizer or Moderna vaccine, the baseline serum binding antibody of people who received the Johnson & Johnson vaccine was 3 to 15 times lower .
-
FDA grants fast-track qualification to efruxifermin for the treatment of non-alcoholic steatohepatitis
Time of Update: 2021-12-04
In addition, earlier this year, Akero announced the positive results of a phase 2a BALANCED study of 30 patients in an extended cohort of 30 patients with efruxifermin in NASH patients with advanced (F4) liver cirrhosis.
-
New research confirms that COVID-19 has flu-like seasonal characteristics
Time of Update: 2021-12-04
In order to understand whether the new coronavirus is a seasonal virus, the research team first analyzed the relationship between the temperature and humidity at the initial stage of the spread of the new coronavirus in 162 countries on five continents before the implementation of relevant measures for epidemic prevention and control .
-
The world's first pig kidney transplantation human body operation completed gene editing and exerted efforts to cultivate high-quality humanized donor pigs
Time of Update: 2021-12-04
It is believed that after years of genetic modification of donor pigs, preclinical test results in non-human primates show that immune rejection has been basically overcome .
"This human trial only verified that the gene-edited pigs overcome the hyperacute rejection of xenotransplantation.
-
Novartis Kymriah's third indication enters the review treatment r/r FL in the U.S. and Europe
Time of Update: 2021-12-04
S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted CD19 CAR-T cell therapy Kymriah (tisagenlecleucel) for supplementary biological product licensing (sBLA) and Class II changes: Treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) who have previously received at least 2 therapies .
-
What makes humans different?
Time of Update: 2021-12-04
▲Schematic diagram of the experimental process of cultivating brain cells with induced pluripotent stem cells from humans and chimpanzees (picture source: reference [1])After a series of analyses such as sequencing the cells obtained after differentiation, the researchers were surprised to find that in the development of human and chimpanzee brain cells, some neglected DNA sequences may play a considerable role, which eventually led to us and chimpanzees.
-
The genetic elicitor that induces the onset of type 1 diabetes may be in the lungs
Time of Update: 2021-12-04
Recently, a research report entitled "Identifying the lungs as a susceptible site for allele-specific regulatory changes associated with type 1 diabetes risk" was published in the international journal Communications Biology.
-
Innotech releases the world's first Ultra Temperature DRAM module
Time of Update: 2021-12-04
Innolux International has targeted the global self-driving car market with a wide temperature range of -40 degrees Celsius to 125 degrees Celsius, helping modern self-driving vehicles and various harsh application environments, effectively combating extreme outdoor high and low temperature differences, and overcoming in-vehicle electronics The large amount of heat generated by the equipment's high-speed calculation enables advanced vehicle technology such as automatic car following and lane departure warning to operate stably while taking into account driving safety .
-
Qiming Medical's transcatheter aortic valve repair system Leaflex(TM) completes the first clinical application in China
Time of Update: 2021-12-04
Zi Zhenjun, Founder and General Manager of Qiming Medical, said: “Leaflex™ is a cost-effective and durable independent treatment method that can improve the severe calcification of the aortic valve.
-
New research reveals the evolutionary reasons for "women are afraid of cold, men are afraid of heat"
Time of Update: 2021-12-04
Recently, researchers from the Faculty of Zoology at Tel Aviv University in Israel provided a new evolutionary explanation for this: This phenomenon is not unique to humans, and many male animals (birds and mammals) prefer lower temperatures than females .
-
Significantly delay the progression of breast cancer
Time of Update: 2021-12-04
On October 20, 2021, Menarini Group and Radius Health announced that the selective estrogen receptor degrading agent (SERD) elacestrant has obtained positive results in a phase 3 clinical trial .
-
Science Sub-Journal: Cracking the mystery that HIV directly causes a rare cancer
Time of Update: 2021-12-04
The relevant research results were published in the Science Advances journal on October 13, 2021, with the title of the paper "Insertional activation of STAT3 and LCK by HIV-1 proviruses in T cell lymphomas" .
-
WuXi Biologics original solution production base has zero defects and completes Health Canada GMP audit
Time of Update: 2021-12-04
HK), the world’s leading open biopharmaceutical technology platform, announced that the company has successfully completed Health Canada’s approval for its Wuxi raw liquid production base.
-
Odivo combined with chemotherapy and neoadjuvant therapy can significantly improve event-free survival in non-small cell lung cancer
Time of Update: 2021-12-03
Princeton, NJ, USA, November 9, 2021/PRNewswire/ - Bristol-Myers Squibb (NYSE: BMY) announced that the Phase III clinical study CheckMate-816 can be cut from Phase IB to Phase IIIA unless minor The primary research endpoint of improving event-free survival (EFS) in patients with cell lung cancer (NSCLC) .
